600 patients66,869 observations120 daysLIVE

Patient P-01835

Synthetic patientNBL-101 · Day 112 · 75+ · F · baseline S17Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
58%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S17
  2. Day 82 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 82 CR-01 recommendedClinician Review CR-01
  4. Day 83 Patient acceptedStarted CR-01 in the companion
  5. Day 88 Deterioration detected before clinical escalationClinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 82.

Primary contributors, last 14 days
  • Inflammatory activity+2
  • Treatment adherence-2
  • Toxicity+2

What helped?

  • Clinician Review CR-01Day 82
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
63%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
61.8/100
stable · +1.0 vs previous 14 d
Toxicity
Blood
55/100
worsening · +2.5 vs previous 14 d
Sleep quality
Wearable
23.5/100
worsening · -3.0 vs previous 14 d
Energy level
Daily log
2.5/10
stable · -0.1 vs previous 14 d
Stress level
Daily log
7.6/10
stable · +0.2 vs previous 14 d
Steps
Wearable
2,494
improving · +126 vs previous 14 d
Adherence
Companion
70.7 %
worsening · -12.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 34 from the failing basin, 62 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 61%
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 64%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 64%
Would not help
  • Keep histamine low
    GI +4.3 next day on high-intake days · n 26
  • Keep simple carbs low
    GI +3.3 next day on high-intake days · n 19
  • Keep fat low
    GI +2.9 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Histamine load
    +4.3detractor · 95%
  • Simple carbohydrates
    +3.3detractor · 95%
  • Dietary fat load
    +2.9detractor · 83%
  • Alcohol
    +2.7detractor · 76%
  • Spicy / capsaicin
    +1.2no signal · 28%
  • Insoluble fibre
    +0.5no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 24/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 60
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 60
    • WearableHRV 15 ms, trending down
  • Drug metabolism and exposure 55
    • DNADPYD *2A → slower clearance
    • BloodToxicity index 55
  • Mucosal barrier integrity 50
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 62 and rising
  • Autonomic recovery 45
    • WearableResting HR 81 bpm
    • Wearable2,494 steps/day
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 24/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
19 ms
Sleep
6.3 h
Steps
2,473
Resting HR
81 bpm
Daily log: GI score 62, nutritional resilience 39, adherence 71.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0189622%S0775
P-0181923%S1372
P-0160423%S0171
P-0138622%S1370
P-0135223%S2070
P-0175022%S1669
P-0169938%S04GI-04improved69
P-0150823%S1868
P-0175422%S1468
P-0150924%S1768
P-0181723%S1467
P-0187740%S01CR-01improved67